1. In
women with
BRCA-associated, newly diagnosed advanced
ovarian cancer, olaparib significantly prolonged progression-free survival (PFS) at three years compared to placebo. 2. The majority of adverse events reported in the olaparib group were low-grade. Among high-grade adverse events, anemia and neutropenia were the most common. Evidence Rating Level: 1 (Excellent) Study Rundown: Though many women with […]